Drug Profile
Research programme: CR1-targeted vaccines - Elusys Therapeutics
Latest Information Update: 22 Apr 2022
Price :
$50
*
At a glance
- Originator Elusys Therapeutics
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Infections
Most Recent Events
- 20 Apr 2022 Elusys Therapeutics has been acquired by Heat Biologics
- 04 Nov 2017 No recent reports of development identified for research development in Infections in USA (Parenteral)
- 14 Sep 2010 This programme is still in active development